Our broad-based transaction experience extends across a range of situations, industries and enterprise values
Categories
Year
Type
Industry
Announced: June 12, 2025Value: $29 billionStatus: ClosedFinancial advisor to Scale AI on its significant new investment from Meta Platforms
Announced: March 7, 2025Value: $26.1 billionStatus: PendingExclusive financial advisor to Walgreens Boots Alliance on the take-private transaction of WBA by Sycamore Partners
Announced: January 27, 2025Value: $16.8 billionStatus: PendingFinancial advisor to Emerson on its acquisition of AspenTech
Announced: January 13, 2025Value: $14.6 billionStatus: PendingCenterview acted as lead financial advisor to Intra-Cellular on its sale to Johnson & Johnson
Announced: March 20, 2025Value: $11 billionStatus: ClosedFinancial advisor to QXO on its acquisition of Beacon Roofing Supply
Announced: June 2, 2025Value: Up to $9.5 billionStatus: PendingFinancial advisor to Blueprint on its sale to Sanofi
Announced: April 8, 2025Value: $8.9 billionStatus: PendingFinancial advisor to Anglo American on the demerger of its platinum group metals business, Anglo American Platinum
Announced: May 5, 2025Value: $7.8 billionStatus: ClosedLead financial advisor to Santander on the sale of its stake in Santander Polska and Santander TFI to Erste Group Bank AG
Announced: April 28, 2025Value: $7.2 billionStatus: PendingFinancial advisor to Mediobanca on its public voluntary exchange offer for 100% of the shares of Banca Generali S.p.A.
Announced: May 27, 2025Value: $4.4 billionStatus: PendingFinancial advisor to Motorola Solutions on its acquisition of Silvus Technologies
Announced: April 28, 2025Value: $3.9 billionStatus: PendingFinancial advisor to SpringWorks on its sale to Merck KGaA
Announced: June 5, 2025Value: $3.4 billionStatus: PendingFinancial advisor to Kimberly-Clark on its sale of a 51% controlling stake in its International Family Care & Professional segment to Suzano S.A.
Announced: January 13, 2025Value: Up to $2.5 billionStatus: PendingCenterview acted as lead financial advisor to Scorpion on its sale to Eli Lilly
Announced: May 14, 2025Value: Up to $2.0 billionStatus: PendingExclusive financial advisor to Boston Pharmaceuticals on its sale of efimosfermin to GSK
Announced: March 17, 2025Value: $1.95 billionStatus: PendingLead financial advisor to PepsiCo on its acquisition of poppi
Announced: February 20, 2025Value: $1.8 billionStatus: PendingFinancial advisor to certain Alani Nu shareholders
Announced: January 14, 2025Value: $1.78 billionStatus: PendingCenterview served as lead financial advisor to Bain Capital and Evident in their sale of Evident's Inspection Technologies division to Wabtec
Announced: June 10, 2025Value: Up to $1.35 billionStatus: PendingExclusive financial advisor to Philogen on its agreement to license the exclusive worldwide rights to develop, manufacture and commercialize OncoAPP3 to Bristol-Meyers Squibb
Announced: April 14, 2025Value: $1.325 billionStatus: PendingLead financial advisor to Lowe's on its acquisition of Artisan Design Group
Announced: January 13, 2025Value: Up to $1.15 billionStatus: ClosedExclusive advisor to IDRx on its sale to GSK
Announced: March 17, 2025Value: Up to $1.1 billionStatus: PendingExclusive financial advisor to Araris on its acquisition by Taiho Pharmaceutical, a subsidiary of Otsuka Holdings
Announced: May 27, 2025Value: Up to $1 billionStatus: PendingExclusive financial advisor to SiteOne on its sale to Eli Lilly
Announced: March 17, 2025Value: Up to $1.0 billionStatus: PendingExclusive financial advisor to EsoBiotec on its acquisition by AstraZeneca
Announced: January 28, 2025Value: Up to $1.0 billionStatus: PendingExclusive financial advisor to Evergreen on its sale to Lantheus
Announced: January 8, 2025Value: Up to $900 millionStatus: PendingExclusive advisor to Bolt on its sale to Boston Scientific
Announced: June 3, 2025Value: $880 millionStatus: PendingExclusive financial advisor to 8th Avenue on its acquisition by Post Holdings
Announced: January 8, 2025Value: $795 millionStatus: PendingServed as financial advisor to Simple Mills on its sale to Flowers Foods
Announced: May 1, 2025Value: $600 millionStatus: PendingExclusive financial advisor to Conagra Brands on its divestiture of the Chef Boyardee brand
Announced: May 21, 2025Value: $470 millionStatus: PendingExclusive financial advisor to Vigil Neuroscience on its sale to Sanofi
Announced: May 6, 2025Value: $350 millionStatus: PendingFinancial advisor to Masimo on the sale of its Sound United consumer audio business to HARMAN International
Announced: February 25, 2025Value: $300 millionStatus: PendingExclusive financial advisor to ChampionX in its divestiture of US Synthetic to LongRange Capital
Announced: May 16, 2025Value: $270 millionStatus: PendingExclusive financial advisor to Inozyme on its sale to BioMarin
Announced: January 29, 2025Value: $250 millionStatus: PendingExclusive financial advisor to Henry Schein in its strategic investment by KKR and board change
Announced: June 17, 2025Value: Up to $1.3bnStatus: PendingLead financial advisor to Verve on its sale to Lilly
Announced: June 2, 2025Status: ClosedFinancial advisor to Entertainment Partners on its acquisition of CASHét
Announced: May 15, 2025Status: PendingExclusive financial advisor to Aetion on its sale to Datavant
Announced: May 12, 2025Status: PendingExclusive financial advisor to Danone on its acquisition of a majority stake in Kate Farms
Announced: March 25, 2025Status: ClosedFinancial advisor to Descartes on its acquisition of 3GTMS
Announced: March 25, 2025Status: ClosedFinancial advisor to Illumina on changes to its Board of Directors
Announced: March 20, 2025Value: Up to $1.9bnStatus: PendingExclusive financial advisor to Dren on the sale of DR-0201 to Sanofi
Announced: March 20, 2025Status: ClosedFinancial advisor to IDG on its sale of Foundry to Regent
Announced: March 12, 2025Status: ClosedFinancial advisor to Zealand Pharma on its global collaboration and license agreement with Roche
Announced: March 5, 2025Value: $935mmStatus: PendingExclusive financial advisor to Chimerix on its sale to Jazz Pharmaceuticals
Announced: March 5, 2025Status: PendingExclusive investment banker and financial advisor to the Ad Hoc Group of Cutera's convertible note holders in its filing for chapter 11 and subsequent comprehensive restructuring transaction
Announced: March 4, 2025Status: PendingSole financial advisor to Repligen on its acquisition of 908 Devices' Bioprocessing PAT portfolio
Announced: February 28, 2025Status: PendingFinancial advisor to Apax on its strategic investment in ECI Software Solutions
Announced: February 27, 2025Status: PendingSole financial advisor to Teleflex on its separation transaction and strategic advisor to the company on its value creation framework
Announced: February 6, 2025Status: PendingFinancial advisor to Honeywell on the separation of its Automation and Aerospace businesses into two separate public companies
Announced: January 22, 2025Status: PendingFinancial advisor to Aptiv on its plan to spin-off its Electrical Distribution Systems business
Announced: January 15, 2025Status: PendingExclusive investment banker to JOANN in its filing for chapter 11 bankruptcy
Announced: January 8, 2025Status: PendingExclusive financial advisor to Alacrity on its strategic transaction for long-term growth
Announced: January 6, 2025Status: PendingFinancial advisor to Advent International on its acquisition of Sauer Brands
Announced: January 6, 2025Status: PendingExclusive financial advisor to The Walt Disney Company in its combination of Hulu and its live TV business with Fubo